Background: SLE is associated with increased risk of overall mortality; however morality trends due to specific causes including cardiovascular disease (CVD), malignancies or other causes are largely unknown. Objectives: Our objective was to assess trends in cause-specific mortality among SLE patients between January 1, 1997 and December 31, 2012 in a general population-based context.
Methods:
We conducted a population-based matched cohort on SLE patients diagnosed between January 1,1997 and December 31,2012 using an administrative health database from the province of British Columbia, Canada. We identified all incident cases of SLE and up to 10 non-SLE controls matched on sex, age, and calendar year of study entry. The cohort was divided into two cohorts based on year of SLE diagnosis (1997-2004 and 2005-2012) . All-cause mortality and cause-specific incidence of death rates (IR) were calculated. Cox proportional hazard regression models were used to estimate the mortality hazard ratios (HR), adjusting for possible confounders (i.e. Charlson Comorbidity Index, number of outpatient visits, hospitalization, cardiovascular medications, glucocorticoids and NSAIDs at baseline). Background: The imbalance of T help 17 cells (Th17)/regulatory T cells (Tregs) is considered to be a pivotal cause of autoimmune diseases 1 , including systemic lupus erythematosus (SLE). However, previous reports 1,2 describing the respective changes of Tregs and Th17 cells in SLE patients were controversial because a few samples or diverse markers were used to identify Tregs with little consensus. Objectives: To clarify the status of Tregs and Th17 in SLE, we investigated the frequencies of Tregs and Th17 cells on a large scale and whether those defects can be corrected by the supplementation of low-dose human recombinant interleukin-2 (IL-2). Methods: Two hundred and thirty-five SLE patients (219 women and 16 men), with mean age of 37.80±14.00 years, were enrolled. The disease activity using European League Against Rheumatism (EULAR) criteria was judged for SLE patients with erythrocyte sedimentation rate (ESR) and SLEDAI scores. The frequencies of CD3+CD4+FOXP3+Treg cells and Th17 cells in peripheral blood from these patients were measured by flow cytometry. And low-dose IL-2 was used among 127 patients at a dosage of fifty WIU every day for five days. Immunological and clinical assessments were performed again at the end of IL-2 treatment. Ninety healthy volunteers, matched for patients' age and gender, were also included for the estimation of CD4+ T cell subsets. Results: As compared to healthy controls (median of Treg cells: 33.09 cells/ul), the frequencies of circulating CD4+CD25+FOXP3+Treg cells were significantly decreased in SLE patients (median: 15.49 cells/ul, P<0.001). The median ratios of Th17/Tregs cells in patients were greatly higher than those of healthy volunteers [0.42 (0.19, 0.88) vs. 0.21 (0.15, 0.34) , P<0.001]. There was not significantly different in circulating Th17 cell between two groups. Moreover, CD4+CD25+FOXP3+Treg cells were negatively correlated with ESR and SLEDAI score (r=-0.198, P=0.01; r=-0.25, P=0.002) .While no obvious correlation was seen between Th17 cells and SLEDAI score. After IL-2 therapy in SLE, there was a fourfold increase in circulating CD4+CD25+FOXP3+Treg cells [43.73 (24.08,74.22) vs. 11.95 (7.51,20.34 
